The buprenorphine market encompasses medications used for treating opioid use disorder and pain. Buprenorphine is a partial opioid agonist, meaning it binds to opioid receptors but with less intensity than full agonists, which helps to reduce cravings and withdrawal symptoms without producing the same level of euphoria or respiratory depression [1].
What forms of buprenorphine are available?
Buprenorphine is available in several formulations. These include sublingual tablets and films, injectable solutions, and implants [2]. Brand names like Suboxone (buprenorphine/naloxone) and Subutex (buprenorphine) are widely recognized for opioid use disorder treatment [3]. Injectable formulations, such as Sublocade, offer longer-acting options [4].
How is buprenorphine regulated?
In the United States, buprenorphine is a Schedule III controlled substance, requiring specific prescribing qualifications for healthcare providers [5]. The Drug Enforcement Administration (DEA) oversees its regulation. Treatment with buprenorphine for opioid use disorder is typically managed under specific clinical guidelines and may involve counseling and behavioral therapy as part of a comprehensive treatment plan [6].
When do buprenorphine patents expire?
Patent expiry dates for buprenorphine products vary depending on the specific formulation and patent. DrugPatentWatch.com tracks these expirations, which can be critical for the development of generic and biosimilar versions of the drug [7]. For example, patents related to the combination product buprenorphine/naloxone films have faced challenges and expirations over time, opening doors for generic competition [8]. Understanding these timelines is crucial for market dynamics and accessibility.
Who are the key manufacturers in the buprenorphine market?
The market for buprenorphine products includes both originator pharmaceutical companies and generic manufacturers. Indivior is a major player, known for brands like Suboxone [3]. Other companies are involved in manufacturing various buprenorphine formulations and are key participants in the generic market following patent expiries [8].
What are the pricing and access considerations for buprenorphine?
Pricing for buprenorphine products can range significantly, with brand-name medications generally being more expensive than their generic counterparts. The cost can be a barrier to access for some patients and healthcare systems. Efforts to increase access often involve expanding the availability of lower-cost generic options and ensuring adequate insurance coverage [9].
What are the clinical uses and benefits of buprenorphine?
Buprenorphine is primarily prescribed for the treatment of opioid use disorder (OUD) as part of Medication-Assisted Treatment (MAT) [1]. It helps to stabilize patients, reduce illicit opioid use, and decrease the risk of overdose and infectious disease transmission associated with injection drug use [6]. It is also used for managing moderate to severe pain [2].
What is the difference between buprenorphine and methadone?
Both buprenorphine and methadone are medications used to treat opioid use disorder. Methadone is a full opioid agonist, while buprenorphine is a partial opioid agonist. Buprenorphine can be prescribed in outpatient settings by a wider range of practitioners once they obtain specific waivers (though these waivers were largely removed in the US in 2023) and is considered to have a lower risk of overdose compared to methadone. Methadone requires dispensing from federally regulated opioid treatment programs [10][11].
What are the potential side effects and risks of buprenorphine?
Common side effects of buprenorphine can include nausea, vomiting, constipation, headache, and sweating [1]. Due to its partial agonist nature, the risk of respiratory depression is lower than with full opioid agonists, but it can still occur, especially when combined with other central nervous system depressants [1]. Precautions are necessary to avoid diversion and misuse [5].
Sources:
[1] National Institute on Drug Abuse. (2023, April 24). Buprenorphine. https://www.drugabuse.gov/publications/research-reports/medications-to-treat-opioid-use-disorder/buprenorphine
[2] National Institutes of Health. (n.d.). Buprenorphine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682349.html
[3] Indivior. (n.d.). Our Medicines. Retrieved from https://www.indivior.com/our-medicines
[4] Sublocade. (n.d.). About Sublocade. Retrieved from https://www.sublocade.com/about-sublocade
[5] U.S. Drug Enforcement Administration. (n.d.). Buprenorphine. Retrieved from https://www.dea.gov/controlled-substances-act
[6] Substance Abuse and Mental Health Services Administration. (n.d.). Medications for Opioid Use Disorder. Retrieved from https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/medications-opioid-use-disorder
[7] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/
[8] Generic Pharmaceutical Association. (n.d.). Buprenorphine/Naloxone Films. Retrieved from https://www.genericpharmaceuticals.org/buprenorphine-naloxone-films/
[9] Kizenko, O. (2023, February 17). The High Cost of Buprenorphine and How to Lower It. The Macro. Retrieved from https://macro.economictimes.indiatimes.com/opinion/the-high-cost-of-buprenorphine-and-how-to-lower-it/97961990
[10] U.S. Food & Drug Administration. (2022, March 29). Medications for Opioid Use Disorder. Retrieved from https://www.fda.gov/patients/drug-shortages/medications-opioid-use-disorder
[11] National Institute on Drug Abuse. (2020, July 1). Methadone. Retrieved from https://www.drugabuse.gov/publications/research-reports/methadone/what-is-methadone